ADUS
NEUTRAL
$101.35
Live
Addus HomeCare Corporation · NASDAQ
Target $140.23
(+38.4%)
$88.96
52W Range
$124.44
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Mar 14, 2026
Market cap
$1.88B
P/E
19.42
ROE
9.3%
Profit margin
6.7%
Debt/Equity
0.16
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
78%
ADUS exhibits mixed financial health with a Piotroski F-Score of 4/9, indicating a weak to stable foundation, and no Altman Z-Score available, which limits distress risk assessment. The stock trades at $101.35, below its intrinsic value of $153.99 and Graham Number of $83.83, suggesting potential undervaluation on a defensive basis. However, strong revenue and earnings growth (25.6% and 52.1% YoY) are tempered by bearish insider activity and a lack of dividend. Analysts maintain a 'buy' recommendation with a target of $140.23, reflecting optimism in future performance.
Key Strengths
Strong earnings growth of 52.1% YoY and 52.5% Q/Q
High revenue growth of 25.6% YoY, outpacing sector average
Attractive intrinsic value of $153.99, implying upside potential
Solid gross margin of 32.47% and operating margin of 11.25%
Low debt/equity ratio of 0.16 and healthy current ratio of 1.80
Key Risks
Piotroski F-Score of 4/9 indicates weak financial strength and limited operational efficiency
Bearish insider sentiment with 19 sell transactions and $2.99M in sales over 6 months
No dividend and zero payout ratio, limiting income appeal
Technical trend is bearish (0/100), with recent 6M and 1M declines of -8.1% and -10.1%
Missing key financials (EV, FCF, cash, debt) limit full health assessment
AI Fair Value Estimate
Based on comprehensive analysis
$153.99
+51.9% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
58
Moderate
82
85
70
52
0
AI Verdict
neutral
Key drivers: Strong growth and undervaluation offset by weak Piotroski score and bearish insider activity, Solid profitability and balance sheet health, Lack of dividend and technical weakness
Confidence
78%
Value
82/100
Ref P/E, PEG, Graham Number
Positives
- Current price ($101.35) is below intrinsic value ($153.99) and Graham Number ($83.83)
- P/E of 19.42 is below sector average of 185.38
- Forward P/E of 13.61 suggests market is pricing in future growth
Watchpoints
- PEG ratio unavailable, limiting growth-adjusted valuation clarity
- Price/Sales of 1.32 is moderate, not deeply undervalued
Future
85/100
Ref Growth rates
Positives
- 25.6% YoY revenue growth and 52.1% earnings growth indicate strong momentum
- Recent Q/Q EPS growth of 13.5% and consistent beat rates (3/4 in last 4 quarters)
- High average earnings surprise of 2.05% over last 4 quarters
Watchpoints
- No PEG ratio to validate growth sustainability
- Forward P/E of 13.61 may be optimistic if growth decelerates
Past
70/100
Ref Historical trends
Positives
- Consistent earnings beat history over 25 quarters, including multiple +10% surprises
- Improving EPS trend from $0.59 in 2020 to $1.77 in 2026
- Strong 1Y return of +11.6% despite 5Y decline of -6.0%
Watchpoints
- 2021 and 2022 saw negative surprises, indicating volatility
- 2022-08-01 and 2021-05-03 missed estimates by 1.5%
Health
52/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Low debt/equity (0.16) and strong current (1.80) and quick (1.63) ratios
- Positive ROE (9.33%) and ROA (6.13%)
- No Altman Z-Score available, but no signs of immediate distress
Watchpoints
- Piotroski F-Score of 4/9 is below threshold for strong financial health
- Missing key metrics (EV, FCF, cash, debt) limit full health assessment
- No Altman Z-Score available, preventing formal distress risk evaluation
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend yield or payout ratio
- Payout ratio is 0.00%
- Dividend strength is 0/100
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$101.35
Analyst Target
$140.23
Upside/Downside
+38.4%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ADUS and closest competitors.
Updated 2026-03-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ADUS
Addus HomeCare Corporation
Primary
|
-6.0% | +1.0% | +11.6% | -8.1% | -10.1% | -1.8% |
|
GRAL
GRAIL, Inc.
Peer
|
+234.0% | +234.0% | +100.6% | -31.0% | -1.5% | -17.0% |
|
ANAB
AnaptysBio, Inc.
Peer
|
+227.2% | +183.1% | +284.9% | +177.0% | +17.3% | +17.0% |
|
AZTA
Azenta, Inc.
Peer
|
-50.6% | -29.6% | -26.9% | +16.3% | +16.1% | +0.1% |
|
AUPH
Aurinia Pharmaceuticals Inc.
Peer
|
-22.4% | +77.0% | +81.0% | +62.7% | -10.7% | -2.1% |
ADU
Addus HomeCare Corporation
Primary
5Y
-6.0%
3Y
+1.0%
1Y
+11.6%
6M
-8.1%
1M
-10.1%
1W
-1.8%
GRA
GRAIL, Inc.
Peer
5Y
+234.0%
3Y
+234.0%
1Y
+100.6%
6M
-31.0%
1M
-1.5%
1W
-17.0%
ANA
AnaptysBio, Inc.
Peer
5Y
+227.2%
3Y
+183.1%
1Y
+284.9%
6M
+177.0%
1M
+17.3%
1W
+17.0%
AZT
Azenta, Inc.
Peer
5Y
-50.6%
3Y
-29.6%
1Y
-26.9%
6M
+16.3%
1M
+16.1%
1W
+0.1%
AUP
Aurinia Pharmaceuticals Inc.
Peer
5Y
-22.4%
3Y
+77.0%
1Y
+81.0%
6M
+62.7%
1M
-10.7%
1W
-2.1%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
19.42
Forward P/E
13.61
PEG Ratio
N/A
P/B Ratio
1.69
P/S Ratio
1.32
EV/Revenue
1.35
EV/EBITDA
12.34
Market Cap
$1.88B
Profitability
Profit margins and return metrics
Profit Margin
6.74%
Operating Margin
11.25%
Gross Margin
32.47%
ROE
9.33%
ROA
6.13%
Growth
Revenue and earnings growth rates
Revenue Growth
+25.6%
Earnings Growth
+52.1%
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
+52.5%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.16
Low debt
Current Ratio
1.8
Good
Quick Ratio
1.63
Excellent
Cash/Share
$4.5
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-04
$N/A
2026-02-23
$1.77
+2.6% surprise
2025-11-03
$1.56
+1.7% surprise
2025-08-04
$1.49
+1.9% surprise
Healthcare Sector Comparison
Comparing ADUS against 393 companies in the Healthcare sector
(24 bullish, 129 neutral, 240 bearish)
P/E Ratio
19.42
This Stock
vs
90.61
Sector Avg
-78.6%
(Discount)
Return on Equity (ROE)
9.33%
This Stock
vs
-101.52%
Sector Avg
-109.2%
(Below Avg)
Profit Margin
6.74%
This Stock
vs
-12.47%
Sector Avg
-154.1%
(Weaker)
Debt to Equity
0.16
This Stock
vs
3.4
Sector Avg
-95.4%
(Less Debt)
Revenue Growth
25.6%
This Stock
vs
124.21%
Sector Avg
-79.4%
(Slower)
Current Ratio
1.8
This Stock
vs
4.56
Sector Avg
-60.5%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ADUS
Addus HomeCare Corporation
|
NEUTRAL | $1.88B | 19.42 | 9.3% | 6.7% | $101.35 | |
|
GRAL
GRAIL, Inc.
|
BEARISH | $1.87B | - | -16.1% | -277.5% | $45.63 | Compare |
|
ANAB
AnaptysBio, Inc.
|
BULLISH | $1.86B | - | -24.5% | -5.6% | $64.81 | Compare |
|
AZTA
Azenta, Inc.
|
NEUTRAL | $1.84B | 77.02 | 1.4% | -9.4% | $40.05 | Compare |
|
AUPH
Aurinia Pharmaceuticals Inc.
|
NEUTRAL | $1.92B | 26.42 | 20.7% | 29.3% | $14.53 | Compare |
ADUS
Addus HomeCare...
NEUTRAL
Mkt Cap
$1.9B
P/E
19.4
ROE
9.3%
Price
$101.35
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-02 | RAINES MONICA | Officer | Sale | 224 | $22,882 |
| 2026-02-25 | ANDERSON DARBY P | Officer | Sale | 1,129 | $120,139 |
| 2026-02-25 | POFF BRIAN | Chief Financial Officer | Sale | 2,861 | $304,741 |
| 2026-02-25 | GAFFNEY SEAN | Officer | Sale | 1,259 | $133,972 |
| 2026-02-25 | ALLISON R DIRK | Chief Executive Officer | Sale | 7,352 | $782,687 |
| 2026-02-25 | TUCKER DAVID W | Officer | Sale | 1,083 | $115,506 |
| 2026-02-25 | WATTENBARGER MICHAEL D | Chief Technology Officer | Sale | 892 | $95,159 |
| 2026-02-25 | STEVENSON ROBERTSON JAMES | Officer | Sale | 851 | $90,790 |
| 2026-02-25 | RAINES MONICA | Officer | Sale | 656 | $69,828 |
| 2026-02-25 | BLESSING CLIFF DONALD | Officer | Sale | 527 | $56,148 |
| 2026-02-23 | ANDERSON DARBY P | Officer | Sale | 666 | $76,530 |
| 2026-02-23 | POFF BRIAN | Chief Financial Officer | Sale | 1,858 | $213,503 |
| 2026-02-23 | GAFFNEY SEAN | Officer | Sale | 737 | $84,689 |
| 2026-02-23 | ALLISON R DIRK | Chief Executive Officer | Sale | 4,535 | $521,117 |
| 2026-02-23 | TUCKER DAVID W | Officer | Sale | 658 | $75,611 |
RAINES MONICA
Officer
2026-03-02
224 shares
·
$22,882
ANDERSON DARBY P
Officer
2026-02-25
1,129 shares
·
$120,139
POFF BRIAN
Chief Financial Officer
2026-02-25
2,861 shares
·
$304,741
GAFFNEY SEAN
Officer
2026-02-25
1,259 shares
·
$133,972
ALLISON R DIRK
Chief Executive Officer
2026-02-25
7,352 shares
·
$782,687
TUCKER DAVID W
Officer
2026-02-25
1,083 shares
·
$115,506
WATTENBARGER MICHAEL D
Chief Technology Officer
2026-02-25
892 shares
·
$95,159
STEVENSON ROBERTSON JAMES
Officer
2026-02-25
851 shares
·
$90,790
RAINES MONICA
Officer
2026-02-25
656 shares
·
$69,828
BLESSING CLIFF DONALD
Officer
2026-02-25
527 shares
·
$56,148
ANDERSON DARBY P
Officer
2026-02-23
666 shares
·
$76,530
POFF BRIAN
Chief Financial Officer
2026-02-23
1,858 shares
·
$213,503
GAFFNEY SEAN
Officer
2026-02-23
737 shares
·
$84,689
ALLISON R DIRK
Chief Executive Officer
2026-02-23
4,535 shares
·
$521,117
TUCKER DAVID W
Officer
2026-02-23
658 shares
·
$75,611
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
13 analysts
Stephens & Co.
2026-02-25
Overweight
Overweight
Barclays
2026-02-24
Underweight
Underweight
BMO Capital
2025-11-13
Market Perform
RBC Capital
2025-11-07
Outperform
Outperform
TD Cowen
2025-11-05
Buy
Buy
Barclays
2025-11-04
Underweight
Underweight
Past News Coverage
Recent headlines mentioning ADUS from our newsroom.
Newest → oldest
No matching news yet.